ANIK
NASDAQ
US
Anika Therapeutics Inc. - Common Stock
$14,80
▼ $-0,18
(-1,20%)
Vol. 99K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$138.6M
ROE
-38,5%
Margine
-29,3%
D/E
0,00
Beta
0,44
52W
$8–$18
Consenso Wall Street
8 analisti · Apr 20263
Acquisto forte
4
Compra
1
Mantieni
0
Vendi
0
Vendita forte
87,5%
Rating Compra
Grafico dei Prezzi
Titoli simili
ARCT
Arcturus Therapeutics Holdings Inc
$174.2M
FENC
Fennec Pharmaceuticals Inc
$262.9M
KRRO
Korro Bio Inc
$75.4M
NVCT
Nuvectis Pharma Inc
$193.4M
SABS
SAB Biotherapeutics Inc
P/E 9,5
$178.0M
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 07, 2026
Stima EPS: $-0,16
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,16 | — | — |
| Dic 2025 | $-0,22 | $0,02 | +$0,24 |
| Set 2025 | $-0,28 | $-0,16 | +$0,12 |
| Giu 2025 | $-0,26 | $-0,28 | $-0,02 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | -$1.3M | $26.2M | $28.2M | $27.8M | $30.6M |
| Utile netto | — | -$21.9M | -$4.9M | -$4.0M | -$2.3M | $292K |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -38.5% | -38.5% | -38.5% | -38.5% | -38.5% | -38.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -14.1% | -49.0% | -49.0% | -49.0% | -49.0% | -29.3% |
| Gross Margin | 50.9% | 56.8% | 56.8% | 56.8% | 56.8% | 54.7% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 |
Rapporti chiave
ROA (TTM)
-29,8%
P/S (TTM)
1,23
P/B
1,6
EPS (TTM)
$-2,28
CF/Share
$-0,69
Crescita ricavi 3A
-6,7%
52W High
$18,37
52W Low
$7,87
$7,87
Intervallo 52 settimane
$18,37
Salute finanziaria
Flusso di cassa libero
$4.0M
Debito netto
-$31.2M
Liquidità
$57.5M
Debito totale
$26.2M
Aggiornato al Dic 31, 2025
Як ANIK виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ANIK vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
1,2
▼
90%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
1,6
▼
36%
sotto
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ANIK vs аналоги Biotechnology
ROE
-38,5%
▲
43%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
-29,3%
▲
90%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
54,7%
▼
30%
sotto
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-29,9%
▲
36%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя ANIK vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
6,2
▲
39%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
0,4
▼
55%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ANIK
ANIK
Mediana peer
Industria
ANIK прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ANIK vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora